+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Thrombosis Drugs Market Size, Share & Trends Analysis Report by Disease Type (Deep Vein Thrombosis, Pulmonary Embolism), Drug Class, Distribution Channel and Region with Growth Forecasts, 2025-2033

  • PDF Icon

    Report

  • 150 Pages
  • November 2025
  • Region: Global
  • Grand View Research
  • ID: 6214506
REQUEST CUSTOMIZATION
Description Jump to:
The global thrombosis drugs market size was estimated at USD 26.11 billion in 2024 and is projected to reach USD 52.30 billion by 2033, growing at a CAGR of 8.03% from 2025 to 2033. The growth of this market is primarily driven by the high prevalence of cardiovascular diseases (CVDs) worldwide, as conditions such as heart attack, stroke, and venous thromboembolism (VTE) increase the demand for effective anticoagulant therapies.

An aging global population further contributes to market growth, since older adults are more susceptible to thrombosis and related complications. Advances in anticoagulant therapies, including safer and more convenient oral options, improve patient outcomes and encourage wider adoption. In addition, the rising prevalence of lifestyle-related diseases such as obesity, diabetes, and hypertension, combined with growing awareness of thrombosis risks and increased healthcare expenditure, continues to support sustained market expansion.

Product innovation and regulatory approvals drive the thrombosis drugs industry by expanding treatment options and raising clinician confidence. Recent drug and device advances, including faster, easier-to-administer clot-dissolving medicines and improved oral anticoagulants, make treatment more effective and simpler to deliver, which supports market growth by increasing clinical uptake. For instance, in March 2025, Genetech's TNKase, a clot-dissolving agent, received the U.S. Food and Drug Administration (FDA) approval for treating acute ischemic stroke (AIS). It is delivered as a single five-second intravenous (IV) bolus, providing a quicker and simpler option than the standard Activase, which requires an IV bolus followed by a 60-minute infusion.

Global awareness initiatives, such as World Thrombosis Day, organized by the International Society on Thrombosis and Hemostasis (ISTH), help to highlight the importance of thrombosis prevention and early detection, thereby indirectly supporting the thrombosis drugs market.

Global Thrombosis Drugs Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of sub-segments from 2021 to 2033. For this study, the analyst has segmented the global thrombosis drugs market report based on disease type, drug class, distribution channel, and region:

To learn more about this report, Download Free Sample Report

Disease Type Outlook (Revenue, USD Million, 2021-2033)

  • Deep Vein Thrombosis
  • Pulmonary Embolism
  • Atrial Fibrillation

Drug Class Outlook (Revenue, USD Million, 2021-2033)

  • Factor Xa Inhibitors
  • Thrombin Inhibitors
  • Heparins
  • P2Y12 Platelet Inhibitors
  • Others

Distribution ChannelOutlook (Revenue, USD Million, 2021-2033)

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Regional Outlook (Revenue, USD Million, 2021-2033)

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listings for you to stay ahead of the curve

This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Disease Type
1.2.2. Drug Class
1.2.3. Distribution Channel
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Thrombosis Drugs Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.3. Pipeline Analysis
Chapter 4. Thrombosis Drugs Market: Disease Type Business Analysis
4.1. Disease Type Market Share, 2024 & 2033
4.2. Disease Type Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Disease Type, 2021 to 2033 (USD Million)
4.4. Deep Vein Thrombosis
4.4.1. Market Estimates & Forecasts, 2021-2033 (USD Million)
4.5. Pulmonary Embolism
4.5.1. Market Estimates & Forecasts, 2021-2033 (USD Million)
4.6. Atrial Fibrillation
4.6.1. Market Estimates & Forecasts, 2021-2033 (USD Million)
Chapter 5. Thrombosis Drugs Market: Drug Class Business Analysis
5.1. Drug Class Market Share, 2024 & 2033
5.2. Drug Class Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2021 to 2033 (USD Million)
5.4. Factor Xa Inhibitors
5.4.1. Market Estimates & Forecasts, 2021-2033 (USD Million)
5.5. Thrombin Inhibitors
5.5.1. Market Estimates & Forecasts, 2021-2033 (USD Million)
5.6. Heparins
5.6.1. Market Estimates & Forecasts, 2021-2033 (USD Million)
5.7. P2Y12 Platelet Inhibitors
5.7.1. Market Estimates & Forecasts, 2021-2033 (USD Million)
5.8. Others
5.8.1. Market Estimates & Forecasts, 2021-2033 (USD Million)
Chapter 6. Thrombosis Drugs Market: Distribution Channel Business Analysis
6.1. Distribution Channel Market Share, 2024 & 2033
6.2. Distribution Channel Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
6.4. Hospital Pharmacies
6.4.1. Market Estimates & Forecasts, 2021-2033 (USD Million)
6.5. Retail Pharmacies
6.5.1. Market Estimates & Forecasts, 2021-2033 (USD Million)
6.6. Online Pharmacies
6.6.1. Market Estimates & Forecasts, 2021-2033 (USD Million)
Chapter 7. Thrombosis Drugs Market: Regional Estimates & Trend Analysis
7.1. Regional Market Share Analysis, 2024 & 2033
7.2. Regional Market Dashboard
7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033
7.4. North America
7.4.1. North America Thrombosis Drugs Market Estimates and Forecasts, by Country, 2021-2033 (USD Million)
7.4.2. U.S.
7.4.2.1. Key Country Dynamics
7.4.2.2. Disease Prevalence
7.4.2.3. Regulatory Framework/Reimbursement Framework
7.4.2.4. Thrombosis Drugs Market Estimates and Forecasts, 2021-2033 (USD Million)
7.4.3. Canada
7.4.3.1. Key Country Dynamics
7.4.3.2. Disease Prevalence
7.4.3.3. Regulatory Framework/Reimbursement Framework
7.4.3.4. Thrombosis Drugs Market Estimates and Forecasts, 2021-2033 (USD Million)
7.4.4. Mexico
7.4.4.1. Key Country Dynamics
7.4.4.2. Disease Prevalence
7.4.4.3. Regulatory Framework/Reimbursement Framework
7.4.4.4. Thrombosis Drugs Market Estimates and Forecasts, 2021-2033 (USD Million)
7.5. Europe
7.5.1. Europe Thrombosis Drugs Market Estimates and Forecasts, by Country, 2021-2033 (USD Million)
7.5.2. UK
7.5.2.1. Key Country Dynamics
7.5.2.2. Disease Prevalence
7.5.2.3. Regulatory Framework/Reimbursement Framework
7.5.2.4. Thrombosis Drugs Market Estimates and Forecasts, 2021-2033 (USD Million)
7.5.3. Germany
7.5.3.1. Key Country Dynamics
7.5.3.2. Disease Prevalence
7.5.3.3. Regulatory Framework/Reimbursement Framework
7.5.3.4. Thrombosis Drugs Market Estimates and Forecasts, 2021-2033 (USD Million)
7.5.4. France
7.5.4.1. Key Country Dynamics
7.5.4.2. Disease Prevalence
7.5.4.3. Regulatory Framework/Reimbursement Framework
7.5.4.4. Thrombosis Drugs Market Estimates and Forecasts, 2021-2033 (USD Million)
7.5.5. Italy
7.5.5.1. Key Country Dynamics
7.5.5.2. Disease Prevalence
7.5.5.3. Regulatory Framework/Reimbursement Framework
7.5.5.4. Thrombosis Drugs Market Estimates and Forecasts, 2021-2033 (USD Million)
7.5.6. Spain
7.5.6.1. Key Country Dynamics
7.5.6.2. Disease Prevalence
7.5.6.3. Regulatory Framework/Reimbursement Framework
7.5.6.4. Thrombosis Drugs Market Estimates and Forecasts, 2021-2033 (USD Million)
7.5.7. Denmark
7.5.7.1. Key Country Dynamics
7.5.7.2. Disease Prevalence
7.5.7.3. Regulatory Framework/Reimbursement Framework
7.5.7.4. Thrombosis Drugs Market Estimates and Forecasts, 2021-2033 (USD Million)
7.5.8. Sweden
7.5.8.1. Key Country Dynamics
7.5.8.2. Disease Prevalence
7.5.8.3. Regulatory Framework/Reimbursement Framework
7.5.8.4. Thrombosis Drugs Market Estimates and Forecasts, 2021-2033 (USD Million)
7.5.9. Norway
7.5.9.1. Key Country Dynamics
7.5.9.2. Disease Prevalence
7.5.9.3. Regulatory Framework/Reimbursement Framework
7.5.9.4. Thrombosis Drugs Market Estimates and Forecasts, 2021-2033 (USD Million)
7.6. Asia-Pacific
7.6.1. Asia-Pacific Thrombosis Drugs Market Estimates and Forecasts, by Country, 2021-2033 (USD Million)
7.6.2. Japan
7.6.2.1. Key Country Dynamics
7.6.2.2. Disease Prevalence
7.6.2.3. Regulatory Framework/Reimbursement Framework
7.6.2.4. Thrombosis Drugs Market Estimates and Forecasts, 2021-2033 (USD Million)
7.6.3. China
7.6.3.1. Key Country Dynamics
7.6.3.2. Disease Prevalence
7.6.3.3. Regulatory Framework/Reimbursement Framework
7.6.3.4. Thrombosis Drugs Market Estimates and Forecasts, 2021-2033 (USD Million)
7.6.4. India
7.6.4.1. Key Country Dynamics
7.6.4.2. Disease Prevalence
7.6.4.3. Regulatory Framework/Reimbursement Framework
7.6.4.4. Thrombosis Drugs Market Estimates and Forecasts, 2021-2033 (USD Million)
7.6.5. Australia
7.6.5.1. Key Country Dynamics
7.6.5.2. Disease Prevalence
7.6.5.3. Regulatory Framework/Reimbursement Framework
7.6.5.4. Thrombosis Drugs Market Estimates and Forecasts, 2021-2033 (USD Million)
7.6.6. South Korea
7.6.6.1. Key Country Dynamics
7.6.6.2. Disease Prevalence
7.6.6.3. Regulatory Framework/Reimbursement Framework
7.6.6.4. Thrombosis Drugs Market Estimates and Forecasts, 2021-2033 (USD Million)
7.6.7. Thailand
7.6.7.1. Key Country Dynamics
7.6.7.2. Disease Prevalence
7.6.7.3. Regulatory Framework/Reimbursement Framework
7.6.7.4. Thrombosis Drugs Market Estimates and Forecasts, 2021-2033 (USD Million)
7.7. Latin America
7.7.1. Latin America Thrombosis Drugs Market Estimates and Forecasts, by Country, 2021-2033 (USD Million)
7.7.2. Brazil
7.7.2.1. Key Country Dynamics
7.7.2.2. Disease Prevalence
7.7.2.3. Regulatory Framework/Reimbursement Framework
7.7.2.4. Thrombosis Drugs Market Estimates and Forecasts, 2021-2033 (USD Million)
7.7.3. Argentina
7.7.3.1. Key Country Dynamics
7.7.3.2. Disease Prevalence
7.7.3.3. Regulatory Framework/Reimbursement Framework
7.7.3.4. Thrombosis Drugs Market Estimates and Forecasts, 2021-2033 (USD Million)
7.8. Middle East and Africa
7.8.1. Middle East and Africa Thrombosis Drugs Market Estimates and Forecasts, by Country, 2021-2033 (USD Million)
7.8.2. South Africa
7.8.2.1. Key Country Dynamics
7.8.2.2. Disease Prevalence
7.8.2.3. Regulatory Framework/Reimbursement Framework
7.8.2.4. Thrombosis Drugs Market Estimates and Forecasts, 2021-2033 (USD Million)
7.8.3. Saudi Arabia
7.8.3.1. Key Country Dynamics
7.8.3.2. Disease Prevalence
7.8.3.3. Regulatory Framework/Reimbursement Framework
7.8.3.4. Thrombosis Drugs Market Estimates and Forecasts, 2021-2033 (USD Million)
7.8.4. UAE
7.8.4.1. Key Country Dynamics
7.8.4.2. Disease Prevalence
7.8.4.3. Regulatory Framework/Reimbursement Framework
7.8.4.4. Thrombosis Drugs Market Estimates and Forecasts, 2021-2033 (USD Million)
7.8.5. Kuwait
7.8.5.1. Key Country Dynamics
7.8.5.2. Disease Prevalence
7.8.5.3. Regulatory Framework/Reimbursement Framework
7.8.5.4. Thrombosis Drugs Market Estimates and Forecasts, 2021-2033 (USD Million)
Chapter 8. Competitive Landscape
8.1. Participant Overview
8.2. Company Market Position Analysis
8.3. Company Categorization
8.4. Strategy Mapping
8.5. Company Profiles/Listing
8.5.1. Bristol-Myers Squibb Company
8.5.1.1. Overview
8.5.1.2. Financial Performance
8.5.1.3. Product Benchmarking
8.5.1.4. Strategic Initiatives
8.5.2. Johnson & Johnson
8.5.2.1. Overview
8.5.2.2. Financial Performance
8.5.2.3. Product Benchmarking
8.5.2.4. Strategic Initiatives
8.5.3. Boehringer Ingelheim International GmbH
8.5.3.1. Overview
8.5.3.2. Financial Performance
8.5.3.3. Product Benchmarking
8.5.3.4. Strategic Initiatives
8.5.4. SANOFI
8.5.4.1. Overview
8.5.4.2. Financial Performance
8.5.4.3. Product Benchmarking
8.5.4.4. Strategic Initiatives
8.5.5. AstraZeneca
8.5.5.1. Overview
8.5.5.2. Financial Performance
8.5.5.3. Product Benchmarking
8.5.5.4. Strategic Initiatives
8.5.6. Pfizer Inc.
8.5.6.1. Overview
8.5.6.2. Financial Performance
8.5.6.3. Product Benchmarking
8.5.6.4. Strategic Initiatives
8.5.7. CSL
8.5.7.1. Overview
8.5.7.2. Financial Performance
8.5.7.3. Product Benchmarking
8.5.7.4. Strategic Initiatives
8.5.8. Novo Nordisk A/S
8.5.8.1. Overview
8.5.8.2. Financial Performance
8.5.8.3. Product Benchmarking
8.5.8.4. Strategic Initiatives
8.5.9. Takeda Pharmaceutical Company Limited
8.5.9.1. Overview
8.5.9.2. Financial Performance
8.5.9.3. Product Benchmarking
8.5.9.4. Strategic Initiatives
8.5.10. Ionis Pharmaceuticals
8.5.10.1. Overview
8.5.10.2. Financial Performance
8.5.10.3. Product Benchmarking
8.5.10.4. Strategic Initiatives
8.5.11. Grifols, S.A.
8.5.11.1. Overview
8.5.11.2. Financial Performance
8.5.11.3. Product Benchmarking
8.5.11.4. Strategic Initiatives
8.5.12. Aspen Holdings
8.5.12.1. Overview
8.5.12.2. Financial Performance
8.5.12.3. Product Benchmarking
8.5.12.4. Strategic Initiatives
List of Tables
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Global thrombosis drugs market, by region, 2021-2033 (USD Million)
Table 4 Global thrombosis drugs market, by disease type, 2021-2033 (USD Million)
Table 5 Global thrombosis drugs market, by drug class, 2021-2033 (USD Million)
Table 6 Global thrombosis drugs market, by distribution channel, 2021-2033 (USD Million)
Table 7 North America thrombosis drugs market, by country, 2021-2033 (USD Million)
Table 8 North America thrombosis drugs market, by disease type, 2021-2033 (USD Million)
Table 9 North America thrombosis drugs market, by drug class, 2021-2033 (USD Million)
Table 10 North America thrombosis drugs market, by distribution channel, 2021-2033 (USD Million)
Table 11 U.S thrombosis drugs market, by disease type, 2021-2033 (USD Million)
Table 12 U.S thrombosis drugs market, by drug class, 2021-2033 (USD Million)
Table 13 U.S thrombosis drugs market, by distribution channel, 2021-2033 (USD Million)
Table 14 Canada thrombosis drugs market, by disease type, 2021-2033 (USD Million)
Table 15 Canada thrombosis drugs market, by drug class, 2021-2033 (USD Million)
Table 16 Canada thrombosis drugs market, by distribution channel, 2021-2033 (USD Million)
Table 17 Mexico thrombosis drugs market, by disease type, 2021-2033 (USD Million)
Table 18 Mexico thrombosis drugs market, by drug class, 2021-2033 (USD Million)
Table 19 Mexico thrombosis drugs market, by distribution channel, 2021-2033 (USD Million)
Table 20 Europe thrombosis drugs market, by country, 2021-2033 (USD Million)
Table 21 Europe thrombosis drugs market, by disease type, 2021-2033 (USD Million)
Table 22 Europe thrombosis drugs market, by drug class, 2021-2033 (USD Million)
Table 23 Europe thrombosis drugs market, by distribution channel, 2021-2033 (USD Million)
Table 24 UK thrombosis drugs market, by disease type, 2021-2033 (USD Million)
Table 25 UK thrombosis drugs market, by drug class, 2021-2033 (USD Million)
Table 26 UK thrombosis drugs market, by distribution channel, 2021-2033 (USD Million)
Table 27 Germany thrombosis drugs market, by disease type, 2021-2033 (USD Million)
Table 28 Germany thrombosis drugs market, by drug class, 2021-2033 (USD Million)
Table 29 Germany thrombosis drugs market, by distribution channel, 2021-2033 (USD Million)
Table 30 France thrombosis drugs market, by disease type, 2021-2033 (USD Million)
Table 31 France thrombosis drugs market, by drug class, 2021-2033 (USD Million)
Table 32 France thrombosis drugs market, by distribution channel, 2021-2033 (USD Million)
Table 33 Italy thrombosis drugs market, by disease type, 2021-2033 (USD Million)
Table 34 Italy thrombosis drugs market, by drug class, 2021-2033 (USD Million)
Table 35 Italy thrombosis drugs market, by distribution channel, 2021-2033 (USD Million)
Table 36 Spain thrombosis drugs market, by disease type, 2021-2033 (USD Million)
Table 37 Spain thrombosis drugs market, by drug class, 2021-2033 (USD Million)
Table 38 Spain thrombosis drugs market, by distribution channel, 2021-2033 (USD Million)
Table 39 Denmark thrombosis drugs market, by disease type, 2021-2033 (USD Million)
Table 40 Denmark thrombosis drugs market, by drug class, 2021-2033 (USD Million)
Table 41 Denmark thrombosis drugs market, by distribution channel, 2021-2033 (USD Million)
Table 42 Sweden thrombosis drugs market, by disease type, 2021-2033 (USD Million)
Table 43 Sweden thrombosis drugs market, by drug class, 2021-2033 (USD Million)
Table 44 Sweden thrombosis drugs market, by distribution channel, 2021-2033 (USD Million)
Table 45 Norway thrombosis drugs market, by disease type, 2021-2033 (USD Million)
Table 46 Norway thrombosis drugs market, by drug class, 2021-2033 (USD Million)
Table 47 Norway thrombosis drugs market, by distribution channel, 2021-2033 (USD Million)
Table 48 Asia-Pacific thrombosis drugs market, by country, 2021-2033 (USD Million)
Table 49 Asia-Pacific thrombosis drugs market, by disease type, 2021-2033 (USD Million)
Table 50 Asia-Pacific thrombosis drugs market, by drug class, 2021-2033 (USD Million)
Table 51 Asia-Pacific thrombosis drugs market, by distribution channel, 2021-2033 (USD Million)
Table 52 Japan thrombosis drugs market, by disease type, 2021-2033 (USD Million)
Table 53 Japan thrombosis drugs market, by drug class, 2021-2033 (USD Million)
Table 54 Japan thrombosis drugs market, by distribution channel, 2021-2033 (USD Million)
Table 55 China thrombosis drugs market, by disease type, 2021-2033 (USD Million)
Table 56 China thrombosis drugs market, by drug class, 2021-2033 (USD Million)
Table 57 China thrombosis drugs market, by distribution channel, 2021-2033 (USD Million)
Table 58 India thrombosis drugs market, by disease type, 2021-2033 (USD Million)
Table 59 India thrombosis drugs market, by drug class, 2021-2033 (USD Million)
Table 60 India thrombosis drugs market, by distribution channel, 2021-2033 (USD Million)
Table 61 Australia thrombosis drugs market, by disease type, 2021-2033 (USD Million)
Table 62 Australia thrombosis drugs market, by drug class, 2021-2033 (USD Million)
Table 63 Australia thrombosis drugs market, by distribution channel, 2021-2033 (USD Million)
Table 64 South Korea thrombosis drugs market, by disease type, 2021-2033 (USD Million)
Table 65 South Korea thrombosis drugs market, by drug class, 2021-2033 (USD Million)
Table 66 South Korea thrombosis drugs market, by distribution channel, 2021-2033 (USD Million)
Table 67 Thailand thrombosis drugs market, by disease type, 2021-2033 (USD Million)
Table 68 Thailand thrombosis drugs market, by drug class, 2021-2033 (USD Million)
Table 69 Thailand thrombosis drugs market, by distribution channel, 2021-2033 (USD Million)
Table 70 Latin America thrombosis drugs market, by country, 2021-2033 (USD Million)
Table 71 Latin America thrombosis drugs market, by disease type, 2021-2033 (USD Million)
Table 72 Latin America thrombosis drugs market, by drug class, 2021-2033 (USD Million)
Table 73 Latin America thrombosis drugs market, by distribution channel, 2021-2033 (USD Million)
Table 74 Brazil thrombosis drugs market, by disease type, 2021-2033 (USD Million)
Table 75 Brazil thrombosis drugs market, by drug class, 2021-2033 (USD Million)
Table 76 Brazil thrombosis drugs market, by distribution channel, 2021-2033 (USD Million)
Table 77 Argentina thrombosis drugs market, by disease type, 2021-2033 (USD Million)
Table 78 Argentina thrombosis drugs market, by drug class, 2021-2033 (USD Million)
Table 79 Argentina thrombosis drugs market, by distribution channel, 2021-2033 (USD Million)
Table 80 Middle East & Africa thrombosis drugs market, by country, 2021-2033 (USD Million)
Table 81 Middle East & Africa thrombosis drugs market, by disease type, 2021-2033 (USD Million)
Table 82 Middle East & Africa thrombosis drugs market, by drug class, 2021-2033 (USD Million)
Table 83 Middle East & Africa thrombosis drugs market, by distribution channel, 2021-2033 (USD Million)
Table 84 South Africa thrombosis drugs market, by disease type, 2021-2033 (USD Million)
Table 85 South Africa thrombosis drugs market, by drug class, 2021-2033 (USD Million)
Table 86 South Africa thrombosis drugs market, by distribution channel, 2021-2033 (USD Million)
Table 87 Saudi Arabia thrombosis drugs market, by disease type, 2021-2033 (USD Million)
Table 88 Saudi Arabia thrombosis drugs market, by drug class, 2021-2033 (USD Million)
Table 89 Saudi Arabia thrombosis drugs market, by distribution channel, 2021-2033 (USD Million)
Table 90 UAE thrombosis drugs market, by disease type, 2021-2033 (USD Million)
Table 91 UAE thrombosis drugs market, by drug class, 2021-2033 (USD Million)
Table 92 UAE thrombosis drugs market, by distribution channel, 2021-2033 (USD Million)
Table 93 Kuwait thrombosis drugs market, by disease type, 2021-2033 (USD Million)
Table 94 Kuwait thrombosis drugs market, by drug class, 2021-2033 (USD Million)
Table 95 Kuwait thrombosis drugs market, by distribution channel, 2021-2033 (USD Million)
List of Figures
Figure 1 Thrombosis drugs market segmentation
Figure 2 Market research process
Figure 3 Data triangulation techniques
Figure 4 Primary research pattern
Figure 5 Market research approaches
Figure 6 Value-chain-based sizing & forecasting
Figure 7 Market formulation & validation
Figure 8 Market snapshot
Figure 9 Therapeutic approach and disease outlook (USD Million)
Figure 10 Competitive landscape
Figure 11 Thrombosis drugs market dynamics
Figure 12 Thrombosis drugs market: Porter’s five forces analysis
Figure 13 Thrombosis drugs market: PESTLE analysis
Figure 14 Thrombosis drugs market: Disease type movement analysis
Figure 15 Thrombosis drugs market: Disease type outlook and key takeaways
Figure 16 Deep vein thrombosis market estimates and forecast, 2021-2033
Figure 17 Pulmonary embolism market estimates and forecast, 2021-2033
Figure 18 Atrial fibrillation market estimates and forecast, 2021-2033
Figure 19 Thrombosis drugs market: Drug Class movement analysis
Figure 20 Thrombosis drugs market: Drug Class outlook and key takeaways
Figure 21 Factor Xa inhibitors market estimates and forecast, 2021-2033
Figure 22 Thrombin inhibitors market estimates and forecast, 2021-2033
Figure 23 Heparins market estimates and forecast, 2021-2033
Figure 24 P2Y12 platelet inhibitors market estimates and forecast, 2021-2033
Figure 25 Others market estimates and forecast, 2021-2033
Figure 26 Thrombosis drugs market: Distribution channel movement analysis
Figure 27 Thrombosis drugs market: Distribution channel outlook and key takeaways
Figure 28 Hospital Pharmacies market estimates and forecast, 2021-2033
Figure 29 Retail pharmacies market estimates and forecast, 2021-2033
Figure 30 Online Pharmacies market estimates and forecast, 2021-2033
Figure 31 Thrombosis drugs market: Regional movement analysis
Figure 32 Thrombosis drugs market: Regional outlook and key takeaways
Figure 33 North America market estimates and forecast, 2021-2033
Figure 34 U.S. market estimates and forecast, 2021-2033
Figure 35 Canada market estimates and forecast, 2021-2033
Figure 36 Mexico market estimates and forecast, 2021-2033
Figure 37 Europe market estimates and forecast, 2021-2033
Figure 38 UK market estimates and forecast, 2021-2033
Figure 39 Germany market estimates and forecast, 2021-2033
Figure 40 France market estimates and forecast, 2021-2033
Figure 41 Italy market estimates and forecast, 2021-2033
Figure 42 Spain market estimates and forecast, 2021-2033
Figure 43 Denmark market estimates and forecast, 2021-2033
Figure 44 Sweden market estimates and forecast, 2021-2033
Figure 45 Norway market estimates and forecast, 2021-2033
Figure 46 Asia-Pacific market estimates and forecast, 2021-2033
Figure 47 Japan market estimates and forecast, 2021-2033
Figure 48 China market estimates and forecast, 2021-2033
Figure 49 India market estimates and forecast, 2021-2033
Figure 50 Australia market estimates and forecast, 2021-2033
Figure 51 South Korea market estimates and forecast, 2021-2033
Figure 52 Thailand market estimates and forecast, 2021-2033
Figure 53 Latin America market estimates and forecast, 2021-2033
Figure 54 Brazil market estimates and forecast, 2021-2033
Figure 55 Argentina market estimates and forecast, 2021-2033
Figure 56 Middle East & Africa market estimates and forecast, 2021-2033
Figure 57 South Africa market estimates and forecast, 2021-2033
Figure 58 Saudi Arabia market estimates and forecast, 2021-2033
Figure 59 UAE market estimates and forecast, 2021-2033
Figure 60 Kuwait market estimates and forecast, 2021-2033
Figure 61 Company categorization
Figure 62 Company market position analysis
Figure 63 Strategic framework

Companies Mentioned

The key companies profiled in this Thrombosis Drugs market report include:
  • Bristol-Myers Squibb Company
  • Johnson & Johnson
  • Boehringer Ingelheim International GmbH
  • SANOFI
  • AstraZeneca
  • Pfizer Inc.
  • CSL
  • Novo Nordisk A/S
  • Takeda Pharmaceutical Company Limited
  • Ionis Pharmaceuticals
  • Grifols, S.A.
  • Aspen Holdings

Table Information

Report AttributeDetails
No. of Pages150
PublishedNovember 2025
Forecast Period2024 - 2033
Estimated Market Value ( USD ) in 2024 $ 26.11 Billion
Forecasted Market Value ( USD ) by 2033 $ 52.3 Billion
Compound Annual Growth Rate8.0%
Regions CoveredGlobal
No. of Companies Mentioned13

Related Topics

Related Reports

Heparin Market 2025-2033 - Product Image

Heparin Market 2025-2033

  • Report
  • 145 Pages
  • Global
From
Anticoagulants Market Report by Drug Class, Route of Administration, Distribution Channel, Application, and Region 2025-2033 - Product Image

Anticoagulants Market Report by Drug Class, Route of Administration, Distribution Channel, Application, and Region 2025-2033

  • Report
  • 144 Pages
  • Global
From
Europe Anticoagulants Market Size and Growth Trends - Share Analysis and Forecast Report 2025-2033 - Product Image

Europe Anticoagulants Market Size and Growth Trends - Share Analysis and Forecast Report 2025-2033

  • Report
  • 200 Pages
  • Europe
From
Anticoagulants Market Global Forecast Report by Drug Class, Route of Administration, Distribution Channel, Application, Countries and Company Analysis 2025-2033 - Product Image

Anticoagulants Market Global Forecast Report by Drug Class, Route of Administration, Distribution Channel, Application, Countries and Company Analysis 2025-2033

  • Report
  • 120 Pages
  • Global
From
Thrombosis Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029 - Product Image

Thrombosis Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

  • Report
  • 130 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.